about
The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future PerspectivesDevelopment, maintenance and disruption of the blood-brain barrierPersonalized medicine in multiple sclerosis: hope or reality?Restoring immune tolerance in neuromyelitis optica: Part IThe astrocyte in multiple sclerosis revisitedAquaporin-4 autoantibodies increase vasogenic edema formation and infarct size in a rat stroke modelLarge-Scale in-House Cell-Based Assay for Evaluating the Serostatus in Patients with Neuromyelitis Optica Spectrum Disorder Based on New Diagnostic Criteria.Frequency of autoantibodies and connective tissue diseases in Chinese patients with optic neuritis.Paraneoplastic neuromyelitis optica spectrum disorder associated with metastatic carcinoid expressing aquaporin-4An immunoassay that distinguishes real neuromyelitis optica signals from a labeling detected in patients receiving natalizumabAquaporins in spinal cord injury: the janus face of aquaporin 4Seroprevalence and specificity of NMO-IgG (anti-aquaporin 4 antibodies) in patients with neuropsychiatric systemic lupus erythematosus.Intravenous neuromyelitis optica autoantibody in mice targets aquaporin-4 in peripheral organs and area postremaPresence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis opticaAbsence of cortical demyelination in neuromyelitis opticaIdentification of two major conformational aquaporin-4 epitopes for neuromyelitis optica autoantibody binding.Regulation of neurovascular coupling in autoimmunity to water and ion channelsDevelopment of a Novel Ligand, [C]TGN-020, for Aquaporin 4 Positron Emission Tomography ImagingBrain-reactive antibodies and disease.Evidence against cellular internalization in vivo of NMO-IgG, aquaporin-4, and excitatory amino acid transporter 2 in neuromyelitis optica.Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytesGhrelin prevents disruption of the blood-brain barrier after traumatic brain injury.Clinical usefulness of cell-based indirect immunofluorescence assay for the detection of aquaporin-4 antibodies in neuromyelitis optica spectrum disorderIκBα deficiency in brain leads to elevated basal neuroinflammation and attenuated response following traumatic brain injury: implications for functional recoveryBrain connexins in demyelinating diseases: therapeutic potential of glial targetsStriatal adenosine signaling regulates EAAT2 and astrocytic AQP4 expression and alcohol drinking in mice.Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss.Intractable nausea and vomiting from autoantibodies against a brain water channelParaneoplastic and other autoimmune disorders of the central nervous system.Reactive astrocytes as therapeutic targets for CNS disorders.Review: the architecture of inflammatory demyelinating lesions: implications for studies on pathogenesis.Paraneoplastic encephalomyelopathies: pathology and mechanisms.Myelination: do astrocytes play a role?ASTROCYTES: EMERGING STARS IN LEUKODYSTROPHY PATHOGENESIS.Features of anti-aquaporin 4 antibody-seropositive Chinese patients with neuromyelitis optica spectrum optic neuritis.Aquaporin-4 deficiency attenuates acute lesions but aggravates delayed lesions and microgliosis after cryoinjury to mouse brain.Aggravated inflammation and increased expression of cysteinyl leukotriene receptors in the brain after focal cerebral ischemia in AQP4-deficient miceDifferences in distribution and regulation of astrocytic aquaporin-4 in human and rat hydrocephalic brain.Stratification of astrocytes in healthy and diseased brain.Blood-brain barrier disruption is more severe in neuromyelitis optica than in multiple sclerosis and correlates with clinical disability.
P2860
Q26767391-017768E9-F0A4-4786-87F5-16A0C27A09EEQ26829668-AE5C638F-F588-4AF8-9AA9-6AAB25901CE1Q27025933-77AA46B9-A258-46BD-B3AE-9582E5404DD1Q28072382-7949079D-33B6-4D81-99B7-CE783CFA830AQ28283441-F8BFD632-6EF0-4ADD-88CF-15A883F5A066Q30953714-C11EA85F-1090-47FD-90A7-06305AC916FBQ33567268-46FFF85C-6075-4389-B70B-CBEA04FC4F1FQ33783819-02316812-1A13-45BF-9D14-385967548504Q33827943-9193E290-EB25-4068-BDA6-CF68FB6234DAQ33895664-E96D3C25-0A41-49E3-8589-7391B48377AAQ33912746-B55F33FC-A71B-4757-BB0E-77CA0EA8EAA1Q34061733-DE7D47DD-3F3B-481C-A098-1391A962047CQ34072723-5976A1FD-0AA8-4470-B5F5-3F0870FABCACQ34338762-89A6AA16-7AEC-4FBE-BDF7-E8678F8313E7Q34370904-826A2EAC-C1FA-4E90-BA1C-AA2F814F878CQ34685499-5E16E473-12B4-4515-920B-5EE9FFA21CA2Q35001946-A6ED9E2E-E9EC-49CC-8DD9-BF2B246E13A8Q35406026-393FB994-54C3-48B5-B290-E779D04B4B1AQ35458567-F650772C-731B-44C6-964B-66B2B994D539Q35639801-D32E5DAF-53EF-4830-9C67-61AE67787A34Q35708842-E7013E07-3CFB-4184-B97A-0EADCADD239CQ35757736-4A502B6D-0380-4FF5-93EB-1EDBB17EFFE9Q36189702-F6A00F65-1EC1-468D-B791-D6E33DABDC96Q36323352-E4B43B67-B3B8-4595-94AF-51EB6CC5D8EDQ36422875-5C64F6DE-082D-4975-AF38-E009549B1F9CQ36540025-A7DC7CAB-A845-4C14-8DEA-7474AC680634Q36635664-AB6152FB-F1B7-4695-8937-7498F2295326Q36636804-ACFCC0A1-75E4-4434-A4AE-19BB862A35C4Q37052800-0743FF4E-ED22-40B1-8314-CAF33C605E79Q37794398-4A6BDEC4-0E6F-4DBD-B10B-B6915612B26EQ37893199-E7767CCE-9885-413B-8F1C-94798786B80CQ37936924-2C4EDEC1-DF63-44B0-9F39-865155E766C8Q38058202-42F70884-1EE1-489F-A680-300171FFB6B3Q38171484-B065DB21-8DD8-4BE0-992D-F895054B7E26Q40750306-FA4305A6-7DA5-48E7-84DA-BF1C929C2BA5Q41441907-82EE486F-8BCE-4C06-BB71-C89B72C91900Q41452642-ED1B4CE3-3796-4161-A4B8-8A8391295277Q44687121-1822BDDB-C3E8-4B3C-A7E4-65EFECBBCD65Q46321594-02A96768-2E85-4026-8EC4-1AA66585BB2BQ48380044-7909734D-B5E8-451E-ABC6-64665C5B408D
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Neurological autoimmunity targeting aquaporin-4.
@en
Neurological autoimmunity targeting aquaporin-4.
@nl
type
label
Neurological autoimmunity targeting aquaporin-4.
@en
Neurological autoimmunity targeting aquaporin-4.
@nl
prefLabel
Neurological autoimmunity targeting aquaporin-4.
@en
Neurological autoimmunity targeting aquaporin-4.
@nl
P1433
P1476
Neurological autoimmunity targeting aquaporin-4
@en
P2093
S R Hinson
V A Lennon
P304
P356
10.1016/J.NEUROSCIENCE.2009.08.032
P407
P577
2009-08-20T00:00:00Z